TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer - Female|Breast Cancer - Male
Interventions: DRUG: Tamoxifen|DRUG: Ribociclib|DRUG: Goserelin
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Novartis